Dr. Jenkins has three decades of experience in operations, business development and consulting. Before joining iBio, he was Senior Vice President CMC at Ridgeback Therapeutics during BLA preparation and eventual approval of ansuvimab. Prior to Ridgeback, Dr. Jenkins worked as a Senior Consultant at Bioprocessing Technology Consultants where he managed CDMO clients in both cell and gene therapy. He’s held technical and business roles in the mammalian cell culture space, helping to establish Catalent’s GPEx technology for mammalian cell line engineering and serving as the General Manager during construction of Catalent’s cGMP manufacturing site in Madison Wisconsin. Additionally, Dr. Jenkins held positions with increasing responsibility at CropTech Corporation, a company with a novel, inducible system to produce recombinant proteins in tobacco plants. Dr. Jenkins has a BS in Microbiology from the University of Illinois and a PhD in Molecular and Cellular Biology from the University of Arizona, where he studied the molecular genetics of UV sensitivity in plants.